Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries

被引：35

作者：

Guglielmetti, L. ^{[1
,2
,3
]}

Hewison, C. ^{[2
]}

Avaliani, Z. ^{[4
]}

Hughes, J. ^{[5
]}

Kiria, N. ^{[4
]}

Lomtadze, N. ^{[4
]}

Ndjeka, N. ^{[6
]}

Setkina, S. ^{[7
]}

Shabangu, A. ^{[8
]}

Sikhondze, W. ^{[9
]}

Skrahina, A. ^{[10
]}

Veziris, N. ^{[3
,11
]}

Furin, J. ^{[12
]}

机构：

[1] Ctr Hosp Bligny, Sanat, Briis Sous Forges, France

[2] Med Sans Frontieres, Paris, France

[3] Univ Pierre & Marie Curie 06, Sorbonne Univ, Ctr Immunol & Malad Infect, Unite 1135,Team Bacteriol E13,Inst Natl Sante & R, Paris, France

[4] Natl Ctr TB & Lung Dis, Tbilisi, Georgia

[5] Med Sans Frontieres, Khayelitsha, South Africa

[6] Natl Dept Hlth, Pretoria, South Africa

[7] Republican Unitary Enterprise, Ctr Examinat & Tests Hlth Serv, Minsk, BELARUS

[8] Natl TB Referral Hosp, Manzini, Swaziland

[9] Natl TB Control Programme, Manzini, Swaziland

[10] Republican Sci & Pract Ctr Pulmonol & TB, Minsk, BELARUS

[11] Hop Univ Pitie Salpetriere Charles Foix, AP HP, Ctr Natl Reference Mycobacteries & Resistance Myc, Paris, France

[12] Harvard Med Sch, 641 Huntington Ave, Boston, MA 02115 USA

来源：

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | 2017年 / 21卷 / 02期

关键词：

tuberculosis; MDR-TB; BDQ; national TB programs; introduction; COMPASSIONATE; PREVALENCE;

D O I：

10.5588/ijtld.16.0493

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

BACKGROUND: For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of introduction, however, has not kept pace with patient needs. It is estimated that as many as 23% of multidrug-resistant TB (MDR-TB) patients have an indication for receiving BDQ. As this is the first time the MDR-TB community is introducing new medications, it is important to understand how implementation can be developed in a variety of settings. METHODS: A qualitative assessment of country TB programs in which more than 5% of MDR-TB patients were started on BDQ under program conditions. RESULTS: National TB programs in Belarus, France, SUMMARY Georgia, South Africa, and Swaziland all started sizeable cohorts of patients on BDQ in 2015. Common factors observed in these programs included experience with compassionate use/expanded access, support from implementing partners, and adequate national or donor-supported budgets. Barriers to introduction included restriction of BDQ to the in-patient setting, lack of access to companion drugs, and the development of systems for pharmacovigilance. CONCLUSION: The five countries in this paper are examples of the introduction of new therapeutic options for the treatment of TB.

引用

页码：167 / 174

页数：8

共 21 条

[1]

[Anonymous], 2015, 25 EUR C CLIN MICR I

[2]

[Anonymous], 2014, USE DELAMANID TREATM

[3] Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study [J].